January 10, 2024 8:05am

Reiterating, “Who will have a seat when the presentations begin, which will benefit from the investment gamut after when the music stops or slows?”

As uncle algo and his electronic trading dwarf’s collect from the upsiders

Pre-open Indications: 4 Sell into Strength, 3 Positive and 1 Negative Indications

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

The pre-open Dow futures are DOWN -0.07% or (-27 points), the S&P futures are UP +0.01% or (+1 points) as the Nasdaq futures are UP +0.07% (+11 points)

Stock futures were mixed on Wednesday morning.

European markets were mixed,

Asia-Pacific markets mostly fell as Japan’s Nikkei 225 surged

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed mixed on Tuesday: as the Dow closed DOWN -157.85 points or -0.42%, the S&P closed DOWN -0.15 points or -7.04% while the Nasdaq closed UP +13.94 points or +0.09%

Markets remain in “wait-and-see mode” as investors ready for the unofficial start of earnings season kicking off Friday with big banks, and brace for two key inflation reports that could inform upcoming Federal Reserve rate decisions.” < Emily Roland, co-chief investment strategist at John Hancock Investment Management>

Economic Data Docket: December’s consumer price index report comes Thursday, followed by the producer price index reading on Friday.

 

Tuesday, RegMed Investors (RMi) Closing Bell: “Volatility is high as selling/profit-taking amplified. News from JPM Healthcare 2024 conference equities weaker locking-in downside.” …  https://www.regmedinvestors.com/articles/13279

 

Q1/24: 1 holiday, 3 negative and 3 positive closes

Q4:

  • December – 1 holiday, 10 positive and 10 negative closes
  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 1 sick day, 9 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength Indication:

Tuesday, Monday’s, Friday, Thursday and last Wednesday, following the previous Tuesday’s closing price “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed UP +$1.25 after Monday +$7.45, Friday down -$2.93 Thursday’s +$1.67, last Wednesday’s -$4.29 and the previous Tuesday’s +$3.52 with a positive +$1.33 or +0.67% pre-open indication.

Sage Therapeutics (SAGE) closed up 1.37 after Monday’s +$3.63, Friday’s +$0.34, Thursday’s -$0.54, Wednesday’s -$0.81 and last Tuesday’s +$0.81 with a positive +$0.53 or +2.01% pre-open indication

Ultragenyx Pharmaceuticals (RARE) closed down -$1.43 after Monday’s +$2.18 and Friday’s +$0.51 with a positive +$1.43 or +2.96% pre-open indication

  • Ultragenyx Pharmaceutical Inc. (RARE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RARE's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."
  • A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.

 

Negative Indications:

Tuesday’s, Monday’s, Friday, Thursday, last Wednesday, and the previous Tuesday’s closing price “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Vericel (VCEL) closed up +$2.52 after Monday’s +$2.27 with a negative -$0.31 or -0.83% pre-open indication.

 

Positive Indications: back from the dump …

Tuesday’s, Monday’s, Friday, Thursday, last Wednesday, and the previous Tuesday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

AxoGen (AXGN) closed down -$0.12 after Monday’s +$0.04 and Friday’s +$1.80 following AXGN announcing POSITIVE preliminary unaudited Q4 and FY2023 revenue after Thursday’s +$0.12 with a positive +$0.19 or +2.24% pre-open indication.

Caribou Bioscience (CRBU) closed flat $0.00 after Monday’s +$0.72, Friday -$0.34 and Thursday’s -$0.04 with a positive +$0.07 or +1.22% pre-open indication.

CRISPR Therapeutics (CRSP) closed down -$0.06 after Monday’s +$2.02, Friday’s -$1.27, Thursday’s -$0.62, last Wednesday’s -$3.50 and the previous Tuesday’s +$3.46 with a positive +$0.67 or +1.077% pre-open indication

 

The BOTTOM LINE: What is the old quote, “the only easy day was yesterday <I seem to remember the pain associated> and it could be coming today … to a number of Monday’s ascending value equities.

  • As I stated in the title, “as uncle algo and his electronic trading dwarfs are STILL circling;” after buying from the JP Morgan Healthcare conference.
  • It was a tough start in 2024 as the cell and gene therapy sector Monday ascended on the 1st day of JPM healthcare conference while Tuesday felt the effects of stripping most upsiders after Friday split pos/neg closes.
  • Investors/traders will eye inflation data this week in the form of the consumer price index (CPI) and producer price index (PPI) to shape expectations for the path of interest rates by the Fed.

Q1/24 – January

  • Tuesday closed down with 14 incliners, 18 decliners and 3 flats,
  • (1/8) Monday closed positive with 28 incliners, 6 decliners and 1 flat
  • Friday closed negative with 12 incliners, 23 decliners and 0 flat
  • Thursday closed positive with 22 incliners, 12 decliners and 1 flat
  • Last Wednesday closed negative with 6 incliners, 29 decliners and 0 flat
  • (1/2) Tuesday closed positive with 21 incliners, 14 decliners and 0 flat

 

My opinion from 12/29/23 ended with “my message of: Looking toward 2024 with one word – recalibration i.e., a change in the way you do or think about something – markets and the cell and gene therapy sector.”

  • I STILL believe the sector is headed into “correction” which means that investors should remain cautious as “our” universe skips into Q4 and 2023’s end earnings’ LPS (loss-per-share) reporting.

 

News, financings, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!

  • It's also a good idea to take some profits, especially if you didn't do so in past sessions. <IBD>

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.